Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Zhu is a 5-star analyst with an average return of 23.4% and a 56.46% success rate. Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Compass Therapeutics.
In a report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $33.00 price target.
Based on Immunome’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $53.84 million. In comparison, last year the company earned a revenue of $2.93 million and had a GAAP net loss of $41.64 million
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2026, Clay Siegall, the President & CEO of IMNM bought 25,450.00 shares for a total of $500,601.50.
